Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: Aspects of the present disclosure relate to genetically altered plants having a heterologous EPR3 or EPR3-like polypeptide or a modified EPR3 or EPR3-like polypeptide and/or having a heterologous EPR3a or EPR3a-like polypeptide or a modified EPR3a or EPR3a-like polypeptide, wherein the EPR3 or EPR3-like polypeptide and/or the EPR3a or EPR3a-like polypeptide provide increased selectivity for a beneficial commensal microbe as compared to a wild-type plant under the same conditions. Other aspects of the present disclosure relate to methods of making such plants as well as cultivating these genetically altered plants. Additional aspects of the present disclosure relate to methods of identifying a beneficial commensal microbe capable of interacting with a plant root microbiota.

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: Compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases.

Abstract: Patients continue to acquire infections from healthcare facilities such as hospitals at an alarming rate. These infections can be transmitted when drugs or other medical materials are delivered from a syringe system into an IV line through an IV port. Some current methods of preventing contamination include swabbing the syringe with alcohol or using disposable alcohol caps; however, these methods are often inefficient. A system is described using caps that cover the entry and exit points of the IV port and the syringe system, respectively. The caps can be temporarily displaced from the entry and exit points when a sufficient force is applied to an area far enough away from the entry and exit points so as to prevent contamination. Once the caps are displaced, the syringe system can interact with the IV port using a locking mechanism such as luer locks to ensure the stability of the connection.

Abstract: Patients continue to acquire infections from healthcare facilities such as hospitals at an alarming rate. These infections can be transmitted when drugs or other medical materials are delivered from a syringe system into an IV line through an IV port. Some current methods of preventing contamination include swabbing the syringe with alcohol or using disposable alcohol caps; however, these methods are often inefficient. A system is described using caps that cover the entry and exit points of the IV port and the syringe system, respectively. The caps can be temporarily displaced from the entry and exit points when a sufficient force is applied to an area far enough away from the entry and exit points so as to prevent contamination. Once the caps are displaced, the syringe system can interact with the IV port using a locking mechanism such as luer locks to ensure the stability of the connection.

Abstract: A business process utilizes computer software and electronic customer/supplier connections to supply information, receive requests for quotation, supply quotations, receive purchase orders, and perform commercial and technical functions associated with delivery of such purchase orders or quotations with respect to environment and use specific products. Such products require customer or plant application unique technical evaluation and/or commercial processing to ensure applicability to a specific customer application. The system provides a vehicle to search for parts requiring such technical review encompassing anticipated product use.

Abstract: A business process utilizes computer software and electronic customer/supplier connections to supply information, receive requests for quotation, supply quotations, receive purchase orders, and perform commercial and technical functions associated with delivery of such purchase orders or quotations with respect to environment and use specific products. Such products require customer or plant application unique technical evaluation and/or commercial processing to ensure applicability to a specific customer application. The system provides a vehicle to search for parts requiring such technical review encompassing anticipated product use.

Abstract: The invention discloses a human cyclooxygenase-2 cDNA, a human cyclooxygenase-2 and assays for preferentially and independently measuring cyclogenase-2 or cyclooxygenase-1 activity present in a given sample.

Abstract: The invention discloses a human cyclooxygenase-2 cDNA, a human cyclooxygenase-2 and assays for preferentially and independently measuring cyclogenase-2 or cyclooxygenase-1 activity present in a given sample.